Filing Details
- Accession Number:
- 0001209191-23-041495
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-06 15:34:22
- Reporting Period:
- 2023-07-03
- Accepted Time:
- 2023-07-06 15:34:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1652130 | Intellia Therapeutics Inc. | NTLA | In Vitro & In Vivo Diagnostic Substances (2835) | 364785571 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1914448 | Eliana Clark | C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139 | Evp, Chief Technical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-07-03 | 360 | $40.51 | 45,146 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Sale of 360 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $40.52, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price.
Billionaire Hedge Funds
